BioSerenity, a Paris, France-based developer of solutions dedicated to personalized patient continuous care, raises €65m in Series B equity funding.
The round was led by Dassault Systèmes (Euronext Paris: #13065, DSY.PA), which invested €50m, with participation from BPI, Idinvest and LBO.
The company intends to use the funds to accelerate the development of sensor-equipped wearables and associated telehealth solutions in the fields of cardiology, neurology and sleep disorders and to grow its business internationally.
Founded in 2014 and led by Pierre-Yves Frouin, President, BioSerenity is a startup developing a comprehensive and efficient health solution involving textiles equipped with sensors and online telehealth services to diagnose and monitor chronic pathologies.
The company, which has been part of the 3DEXPERIENCE Lab, is developing wearable medical devices and digital point-of-care solutions that leverage textile innovation and artificial intelligence, as well as electronic patient-reported outcome (ePRO), internet of things and cloud technologies.
It provides hospitals and healthcare professionals with a portfolio of fully-operated care services. BioSerenity also provides pharmaceutical companies with solutions for companion diagnostics.